Biotechnology
Top Biotechnology Stocks To Watch After Latest News
Biotechnology stocks have had a wild year so far. The latest trend to start October has been bullish, to say the least. Nothing quite symbolizes this market better than the iShares Biotech ETF (IBB). If you look at a chart, you’ll see a strong push at the start of 2019, followed by a steady decline.
But as many will notice, this month has seen a sharp reversal in biotech stocks which could indicate a green light to start paying attention to this industry in the 4th quarter.
One of the most important things that a health sciences company can do is communicate material news with the public. Whether that is updates on Phase Trials or upcoming conference presentations, content is king. With this in mind, let’s take a closer look at 3 biotech stocks to watch after some recent news.
Biotech Stocks To Watch #1: GT Biopharma (GTBP)
One of the cornerstones of biopharmaceuticals is oncology & immunotherapy. GT Biopharma (GTBP) has built a pipeline of treatments to address the growing need for novel therapy. One of the more recent developments that investors are watching with GT Biopharma is its success with NK Cells and HIV. This month the company announced that Tim Schacker , M.D., Jeffrey S. Miller , M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg discussing their design of an HIV-TriKE™.
In The News: GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells
The significance of this could be unprecedented. Why? Despite the use of anti-retroviral drugs, infected individuals retain reservoirs of latent HIV-infected cells that, upon cessation of anti-retroviral drug therapy, can reactivate and re-establish an active HIV infection. For a curative therapy, destruction of these latent HIV infected cells must take place.
GT Biopharma (GTBP) presented data indicating a potential role for the HIV-TriKE™ in the reactivation and elimination of latently infected HIV reservoir cells. This was accomplished by harnessing the NK cell’s ability to mediate the “antibody-directed cellular cytotoxicity” or “ADCC”.
Full Report On GT Biopharma (GTBP) Here
Biotech Stocks To Watch #2: Advaxis, Inc. (ADXS)
In line with this, Advaxis Inc. (ADXS) announced more survival data from a Phase 1/2 KEYNOTE-046 study. The trial is being conducted in unison with Merck to evaluate ADXS-PSA along and combined with KEYTRUDA. ADXS-PSA is Advaxis’ thereapy used to treat prostate cancer.
As part of the findings, Kenneth A. Berlin, President and Chief Executive Officer of Advaxis said, “We believe that ADXS-PSA in combination with KEYTRUDA® has the potential to be an important new treatment option for patients with advanced metastatic, castration-resistant prostate cancer, which based on these data, warrants further evaluation. We are currently assessing next steps for a potential new study for ADXS-PSA in combination with KEYTRUDA® in mCRPC and we look forward to providing additional details about the program’s path forward.”
Advaxis has three programs in various stages of clinical development: ADXS-NEO, a personalized neoantigen-directed therapy designed, in principle, for any solid tumor; ADXS-503 for non-small cell lung cancer, from its ADXS-HOT off-the-shelf neoantigen-directed program, in addition to ADXS-PSA.
Biotech Stocks To Watch #3: Sienna Biopharmaceuticals, Inc. (SNNA)
This week, Sienna Biopharmaceuticals, Inc. (SNNA) has also seen a push after recent news was published this month. The main focus has been on the company filing a Premarket Notification 510(k) submission to the FDA for its SNA-001. The purpose of the 510(k) notification is to allow for commercial use of SNA-001. So what does SNA-001 do? Primarily, this is used for hair removal.
SNA-001 is a topical, ready-to-use suspension applied to the treatment area on the skin and delivered into the pores. With this 510(k) approval, SNA-001 in will be used in conjunction with a 810 nm Diode laser for the removal of unwanted light hair. Shares have moved from lows of $0.10 at the end of September to highs of $0.36 this week.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.
There are very few sectors in the stock market that have consistently produced winning trades. You might be able to count such sectors on one hand. Biotech is certainly among those sectors due to the emergence of highly innovative companies. These firms tend to create new avenues of creation to address unmet medical needs.
There are plenty of promising companies in the sector but it is necessary for an investor to do research thoroughly. It makes finding the best biotech stocks a bit easier. Though no one’s guaranteed a win, sifting out bad stocks is the key. One must watch the market closely to come across promising biotech stocks. Here is a look at two biotech stocks that are worth watching.
Biotech Stocks To Watch: Moleculin Biotech (MBRX)
The first biotech stock to consider is that of Moleculin Biotech Inc (NASDAQ:MBRX), which made some gains on Wednesday on the back of positive interim results for one of its products. The company, which is involved in manufacturing medicines meant for extremely resistant tumors, released data with regards to its acute myeloid leukaemia medicine annamycin.
Moleculin revealed highly positive interim data from the Phase ½ clinical study of the medicine and naturally, it has resulted in a lot of excitement in the market with regards to the stock. The stock rose by as much as 2% on the back of the news in yesterday’s trading session. It is one of the key biotech stocks to keep an eye on over the coming days.
Biotech Stocks To Watch: Eyepoint Pharmaceuticals (EYPT)
The other biotech stock that has recorded impressive gains on the market today is the Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) stock. On Wednesday, the company announced an important deal with regard to dexamethasone intraocular suspension 9% (DEXYCU). Eyepoint announced that it has managed to reach an agreement with one of the biggest players in the U.S. integrated delivery systems.
[Read More] 3 Pharma Stocks To Watch In December 2019
The deal is for two years and the other party is going to offer DEXYCU in its aforesaid systems. It is a major boost for Eyepoint and it has resulted in 5% to close at $1.54 in Wednesday’s trading session.
The biotech sector has thrown plenty of winners over the course of the last decade or so and if experts are to be believed then it is going to continued to do so for the foreseeable future. Great advancements are being made in the biotech industry and many companies are working on a highly advanced product.
In such a situation, it is imperative for an intelligent investor to look for companies worth investing in. One should watch the latest developments in the sector and track specific companies closely. Here is a look at two biotech stocks that are worth watching.
Neoleukin Therapeutics
The first biotech stock to watch is that of Neoleukin Therapeutics Inc (NLTX), which has managed to gain significantly over the past two weeks. On November 13, the company released its third-quarter results and since then it has rocketed by as much as 75%. The Canadian company made a loss of $59.1 million in the quarter, which worked out to $2.26 per share.
The company is a biopharmaceutical company that is involved in immunotherapies using de novo protein design technology. The company’s lead product candidate is NL-201, which is an amalgamation of both IL-2 and IL-15 and helps in removing alpha receptor binding.
Verastem
The other biotech stock that is worth watching is Verastem Inc (NASDAQ:VSTM). It made significant gains over the past week. On Monday, the company announced that it has submitted a Marketing Authorization Application for its product COPIKTRA to the European Medicines Agency.
COPIKTRA is a phosphoinositide 3-kinase. It’s meant for patients suffering from refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).
The company is seeking approval for the same in the European market. Verastem stated that it has seen significant improvement in patients who used the product. The stock rocketed by as much as 60% after the news broke and remains one of the stocks to watch this week.
Biotech is a sector that has grown significantly over the past decade or so and continues to hold a lot of promise if market experts are be believed. Hence, it is no surprise that investors are almost always on the lookout for the next winners from among the hundreds of penny stocks in the market.
However, if one has to identify a promising stock, then he has to watch the market closely and do his own research quite thoroughly. Here is a look at two biotech stocks that should be watched closely by all investors.
Oramed Pharmaceuticals Hits New Highs
The first biotech stock that should be put into the watch list is that of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). The company, which is engaged in developing oral drug delivery systems, announced highly positive results from the Phase 2b trial of its product ORMD-0801.
The product in question is an oral insulin treatment and if it is eventually approved then it would become the very first orally administered insulin product. Hence, the optimism around the product and the Oramed stock is perfectly understandable.
Over the course of the past two weeks, the stock has gained by as much as 135%. Moreover, the stock made a new 52-week high of $5.80 in Monday’s trading session.
Clearside Biomedical Jumps 70% in 2-Week
The other biotech stock that has enjoyed an impressive rally in recent times is that of Clearside Biomedical Inc (NASDAQ:CLSD). The company developed a specially designed suprachoroidal space (SCS) microinjection platform. It helps administer medicines to the eyes. One of the most important medicines in its pipeline, Xipere, treats macular edema. The disease can seriously affect a person’s eyesight.
Earlier this year, the company announced that it had decided to postpone Xipere due to issues with its contractors. However, a complete response letter from the FDA in October revealed that the regulatory body needed more information about the medicine. The information demanded did not include anything that was related to the effectiveness of the medicine. The stock has gained 70% over the past two weeks.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
-
Entertainment2 weeks agoHow Should You Trade ROKU Stock Amid Growing Streaming Business
-
Biotechnology6 days ago3 Pharma Stocks To Watch In December 2019
-
Entertainment1 week agoIs It Time To Buy Or Sell Netflix; Streaming Wars Heat Up
-
Entertainment1 week agoDisney (DIS) Streaming Business is Getting 1 Million Subscribers a Day
-
Featured2 weeks agoStock Price Newsletter – November 26, 2019
-
Featured1 week ago
Stock Price Black Friday Newsletter – November 29, 2019
-
Featured6 days agoStock Price Monday Morning Update – December 2, 2019
-
Entertainment2 weeks agoStreaming Wars: Is This The Best Strategy To Capitalize With?